Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

10x Genomics at Jefferies Global Healthcare Conference: atera gains momentum

10x Genomics at Jefferies Global Healthcare Conference: atera gains momentum

On Tuesday, November 17th, 2026, 10x Genomics presented at the Jefferies Global Healthcare Conference to showcase its strong third quarter performance and the potential of its new Atera spatial transcriptomics platform. The company highlighted the launch as a positive development while acknowledging challenges such as product mix shifts, pricing pressure, and supply-demand strain. Atera has emerged as the main growth driver, with increasing customer interest, orders, and pipeline activity surpassing initial expectations.

Notably, over half of the early demand for Atera comes from customers new to spatial biology, not just those who already use Xenium instruments. Even though Xenium consumables grew mid-single digits in the Q3, the company still experienced operational strain due to demand outpacing supply. Management sees Atera as a key platform for AI foundation models and is developing a clinical pathway focused on oncology evidence generation and CLIA lab work.

The company generated approximately $100 million in cash over the past 12 months and has room for strategic M&A, though they prioritize organic growth.

10x Genomics reported $618.6 million in revenue for the trailing 12 months ending in Q3 2026, with a gross profit margin of 72%. Despite recent losses, financial analysts predict that the company will become profitable this year. Xenium consumables experienced mid-single-digit sequential growth, outperforming management's expectations, while single-cell consumables increased by 1% year-over-year, though pricing pressure from the Flex Apex transition impacted revenue. Chromium Flex Apex showed double-digit growth in reaction volume despite falling average pricing.

The company has generated about $100 million in cash over the trailing 12 months, and management claims its strong balance sheet can support strategic M&A opportunities. Current ratio stands at 5.12, with moderate debt levels of $75.8 million. CFO Adam expects consumables growth to improve as Apex conversion dynamics stabilize and believes the business will reach equilibrium within a couple of quarters.

CEO Serge stated that Atera demand has been stronger than expected, with more than 50% of initial orders and pipeline opportunities coming from customers without existing Xenium instruments, including non-traditional life sciences users like Procter & Gamble. The company anticipates selling 50 Atera instruments in 2024 and expects to scale production to 50 units per quarter starting in Q1 2025.

Serge noted that customer interest and applications have exceeded initial expectations, and operational limits are already being encountered, particularly in field service engineering and customer success infrastructure.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

More in Finance & Markets

More from Tuesday 17 November →